Wednesday, 08 December 2021

Bayer to invest over €400 M for access to modern contraception

06 October 2021 | News

The initiative will provide 100 million women and girls with access to family planning by 2030, especially in low- and middle-income countries

Image Credit: Shutterstock

Image Credit: Shutterstock

Bayer will invest over €400 million, reinforcing its commitment to providing 100 million women and girls with access to family planning by 2030, especially in low- and middle-income countries (LMICs). This investment will include the expansion of production capabilities in Turku, Finland and the construction of a new production site in Alajuela, Costa Rica.

 

In Costa Rica, Bayer will build a new state-of-the-art production facility, specialised in the production and supply of LARCs. The new production plant at Coyol Industrial Park, Alajuela, Costa Rica, is expected to start the supply of long-acting reversible contraceptives to LMICs by 2024.

 

The company will also invest substantially in building a new facility and expanding its production capabilities in Turku, Finland, as announced earlier this year. Upon completion by 2025, the new production facility will boast the latest technology, leveraging automation and robotics to produce long-acting reversible contraceptives.

 

Both sites will produce hormonal implants and hormonal intrauterine systems (IUS), supporting Bayer to achieve its global sustainability goal of providing 100 million women and girls in LMICs with access to family planning by 2030. The investment will also support Bayer, a leader in women’s healthcare with an innovative and successful IUS product portfolio, in strengthening its commercial supply chain.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

//Survey Form JS Starts //Survey Form JS Ends